Crispin Hiley, UK Clinical Director for Lung Cancer at GenesisCare, shared a post on X:
“Slick discussion of complexity post Osimertinib decision making for patients with EGFR mutation positive NSCLC by Stephanie Saw – it’s a good problem to have in 2025.”
